8-K: Regulus Therapeutics Announces Positive Phase 1b Data and Q2 2024 Financial Results

Regulus Therapeutics reported positive topline data from their Phase 1b study of RGLS8429 for ADPKD and announced their Q2 2024 financial results, ending the quarter with $95.9 million in cash.

Summary

• Regulus Therapeutics announced positive topline data from the third cohort of their Phase 1b MAD study of RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD).
• The data showed continued improvement in polycystin levels and reductions in kidney volume after three months of treatment.
• 70% of patients in the third cohort showed reductions in height adjusted total kidney volume (htTKV).
• The company is on track for an End-Of-Phase 1 meeting with the FDA by the end of 2024.
• Regulus appointed Rekha Garg, M.D., M.S., as Chief Medical Officer.
• The company ended the second quarter of 2024 with $95.9 million in cash, cash equivalents, and investments, which is expected to fund operations into the first half of 2026.
• Research and development expenses were $8.3 million for the three months ended June 30, 2024, and $14.3 million for the six months ended June 30, 2024.
• General and administrative expenses were $4.0 million for the three months ended June 30, 2024, and $6.7 million for the six months ended June 30, 2024.
• The net loss was $11.0 million, or $0.17 per share, for the three months ended June 30, 2024, and $19.5 million, or $0.41 per share, for the six months ended June 30, 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and a strong cash position, indicating a positive outlook for the company. However, the increased expenses and net loss temper the overall sentiment slightly.

Positives

• The Phase 1b MAD study of RGLS8429 showed positive results with continued improvement in polycystin levels and reductions in kidney volume.
• RGLS8429 was well tolerated with no safety concerns.
• The company has a strong cash position of $95.9 million, providing a cash runway into H1 2026.
• The appointment of Rekha Garg as Chief Medical Officer strengthens the executive leadership team.
• Regulus was added to the Russell 3000 and Russell 2000 Indexes.

Negatives

• The company reported a net loss of $11.0 million for the three months ended June 30, 2024, and $19.5 million for the six months ended June 30, 2024.
• Research and development expenses increased to $8.3 million for the three months ended June 30, 2024, and $14.3 million for the six months ended June 30, 2024, compared to the same periods in 2023.
• General and administrative expenses also increased to $4.0 million for the three months ended June 30, 2024, and $6.7 million for the six months ended June 30, 2024, compared to the same periods in 2023.

Risks

• The development of RGLS8429 is novel and may not lead to marketable products.
• Preliminary or topline results may change following a more comprehensive review of the data.
• The FDA has not designated RGLS8429 for an Accelerated Approval pathway, and such designation may not lead to faster development or approval.
• Preclinical and clinical studies may not be successful.
• The company relies on third-party collaborators and other third parties.
• There are risks related to intellectual property.
• Additional toxicology data may be negative.
• The company may not be able to successfully secure and deploy capital.

Future Outlook

The company expects its cash runway to extend into H1 2026 and plans to request an end of Phase 1 meeting with the FDA in the fourth quarter of 2024. Topline data from the fourth cohort of the Phase 1b MAD study is expected in early 2025.

Management Comments

• Jay Hagan, CEO of Regulus, stated that the data from cohort three showed continued improvement on both polycystin and height adjusted total kidney volume after just three months of treatment.
• Jay Hagan also mentioned that the growing data set leaves them excited about the potential of RGLS8429 as a treatment for ADPKD.

Industry Context

Regulus is developing a novel oligonucleotide therapy for ADPKD, a disease with limited treatment options, placing them in a competitive space with other companies developing treatments for kidney diseases. The positive data from the Phase 1b study could position them well in the market if the drug continues to show efficacy and safety.

Comparison to Industry Standards

• The 70% reduction in htTKV in the third cohort is a positive signal, but it is important to compare this to other ADPKD treatments in development, such as Tolvaptan, which has shown a slower rate of kidney volume growth.
• Companies like Otsuka Pharmaceutical, which markets Tolvaptan, are key competitors in the ADPKD space, and Regulus will need to demonstrate superior efficacy and safety to gain market share.
• The company's cash runway into H1 2026 is a positive sign, but it will need to continue to raise capital to fund its clinical trials and commercialization efforts.
• The increase in R&D expenses is expected for a company in clinical development, but it will need to manage these costs effectively to maintain a healthy financial position.

Management Changes

Stakeholder Impact

• Shareholders may view the positive clinical data and strong cash position favorably.
• Employees may be encouraged by the company's progress and financial stability.
• Patients with ADPKD may have hope for a new treatment option.
• Creditors may view the company as a lower risk due to its cash runway.

Next Steps

• Enrollment and treatment of patients in the fourth cohort of the Phase 1b MAD study.
• Request an end of Phase 1 meeting with the FDA in the fourth quarter of 2024.
• Provide topline data from the fourth cohort in early 2025.
• Discuss the potential for a pivotal Phase 2/3 study of RGLS8429 under an Accelerated Approval regulatory pathway.

Key Dates

Keywords

RGLS8429, ADPKD, Autosomal Dominant Polycystic Kidney Disease, Phase 1b MAD study, microRNA, Oligonucleotide, Clinical Trial, Biopharmaceutical, FDA, Drug Development